🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Intrafraction motion of the prostate during RT: how often does it happen, what increases the likelihood of occurrence, and what can and should be done about it? See our review in #PracticalRO @Astro_org, led by Aoi Shimomura. Abhishek Solanki @amarUkishan Alison Tree 💙 #radonc #pcsm

ASTRO Aoi Shimomura Abhishek Solanki Amar Kishan Alison Tree 💙 authors.elsevier.com/a/1i6SE6hRQmsY…

Thanks for inviting me. It was fun being back in the old stomping grounds and meeting all the residents and old friends!

Poll for US Bladder Cancer RadOnc Community. For clinically node negative MIBC (T2/T3) treating bladder only, my choice of RT fractionation for curative intent chemoRT is:

Promising developments in the treatment of prostate cancer from the SOLAR Phase 2 Trial, demonstrating effective treatment strategies that aim to reduce the necessity for traditional, more aggressive methods. #VAResearch europeanurology.com/article/S0302-…

Register today for a #PatientSafety Conversation Hour on Thursday, May 30, from 1-2 p.m. ET. During this virtual conversation hour, attendees will discuss curated RO-ILS events in a small group and then debrief with safety experts. Learn more: ow.ly/PEgh50RohqR

#ASCO24 TiP: VA STARPORT: Ph 3 trial of PET-directed local therapy addition to systemic therapy in oligometastatic PCa (≤10 lesions on PSMA PET) 🔹Primary outcome: CRPC-free survival UroToday.com Abhishek Solanki

#ASCO24 TiP: VA STARPORT: Ph 3 trial of PET-directed local therapy addition to systemic therapy in oligometastatic PCa (≤10 lesions on PSMA PET) 🔹Primary outcome: CRPC-free survival UroToday.com Abhishek Solanki

#VeteransAffairs seamless phase II/III randomized trial of standard systemic therapy with or without PET-directed local therapy for oligometastatic #ProstateCancer VA STARPORT. Presented by Abhishek Solanki Loyola University Chicago > bit.ly/3Kxw1fn Veterans Affairs Rashid K. Sayyid

I wanted to share a manuscript led by our former resident Anjali Saripalli, MD MSE. We reviewed the existing data on intraprostatic radiorecurrent #PCSM and made practical recommendations on workup and re-RT planning and delivery. Amar Kishan BhanuPrasad Venkatesulu rdcu.be/dTPBy

F-SHARP: Initial results of a multi-institutional phase 1/2 trial of focal dose-escalated salvage HDR brachytherapy for radiorecurrent #ProstateCancer. Presentation by Abhishek Solanki Loyola University Chicago. #ASTRO24 written coverage by Zach Klaassen Georgia Cancer Center >

Focal dose-escalated salvage high dose rate brachytherapy demonstrated safety and efficacy in patients with radiorecurrent prostate cancer, according to data from the phase 1/2 F-SHARP trial. #ASTRO24 #pcsm Abhishek Solanki urologytimes.com/view/focal-sal…

Register today for the Definitive and Salvage Radiation Therapy for Prostate Cancer: The Management of Locally Radiorecurrent Prostate Cancer webinar taking place on 11/6 at 12 p.m. ET. ow.ly/ywbV50TI7E4 Abhishek Solanki Radiation Oncology | Dartmouth Cancer Center BhanuPrasad Venkatesulu

Peer review in #RadiationOncology changes 1 in 4 treatment plans, per a meta-analysis of nearly 100K cases. Dr. Solanki: “A collaborative process that benefits patients by ensuring the best care.” bit.ly/4hjhLpi #RadOnc Abhishek Solanki

Decipher risk strat of radiorecurrent PCa: Correlative analysis of the F-SHARP trial of salvage re-RT Abhishek Solanki UroToday.com #GU25 ☑️Higher Decipher score: - ⬆️risk of bPFS: HR 1.70, 95%1.05-2.75 - ⬆️risk of LRFS: HR 2.30, 95%CI 1.02-5.18 - ⬆️risk of rPFS: HR 2.47,

#Decipher risk stratification of radiorecurrent #ProstateCancer: Correlative analysis of the F-SHARP trial of salvage reirradiation. Presentation by Abhishek Solanki Loyola University Chicago. #GU25 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/4gNpX0j Decipher by Veracyte

In this #RedJournal study, BhanuPrasad Venkatesulu, Abhishek Solanki et al. analyzed the F-SHARP clinical trial of salvage HDR brachytherapy for radiorecurrent #PCSM and found that MRI & PET/CT can help identify a radiorecurrence. Read it here: tinyurl.com/redsolanki

The Evolving Management of Radiorecurrent Prostate Cancer. pubmed.ncbi.nlm.nih.gov/40516980/